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APPLIED PHYSICS REVIEWS—FOCUSED REVIEW
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In regard to cancer therapy, magnetoelectric nanoparticles (MENs) have proven to be in a class of its
own when compared to any other nanoparticle type. Like conventional magnetic nanoparticles, they
can be used for externally controlled drug delivery via application of a magnetic field gradient and
image-guided delivery. However, unlike conventional nanoparticles, due to the presence of a non-
zero magnetoelectric effect, MENs provide a unique mix of important properties to address key chal-
lenges in modern cancer therapy: (i) a targeting mechanism driven by a physical force rather than
antibody matching, (ii) a high-specificity delivery to enhance the cellular uptake of therapeutic drugs
across the cancer cell membranes only, while sparing normal cells, (iii) an externally controlled
mechanism to release drugs on demand, and (iv) a capability for image guided precision medicine.
These properties separate MEN-based targeted delivery from traditional biotechnology approaches
and lay a foundation for the complementary approach of technobiology. The biotechnology approach
stems from the underlying biology and exploits bioinformatics to find the right therapy. In contrast,
the technobiology approach is geared towards using the physics of molecular-level interactions
between cells and nanoparticles to treat cancer at the most fundamental level and thus can be
extended to all the cancers. This paper gives an overview of the current state of the art and presents
an ab initio model to describe the underlying mechanisms of cancer treatment with MENs from the
perspective of basic physics.VC 2017 Author(s). All article content, except where otherwise noted, is
licensed under a Creative Commons Attribution (CC BY) license (http://creativecommons.org/
licenses/by/4.0/). [http://dx.doi.org/10.1063/1.4978642]
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I. INTRODUCTION
Achieving adequately high specificity to target cancer
cells while sparing normal cells remains one of the greatest
challenges in cancer therapy to date.1–3 Ongoing research has
attempted to address this fundamental challenge by using
nanoparticles as targeted delivery vehicles. Due to their small
sizes and unique shapes, nanoparticles can help steer a thera-
peutic load to specific targets and meet a wide range of
requirements for overcoming numerous biological barriers.4–10
There are endless types of nanoparticle delivery systems, both
passive and active, constantly being developed. Passive sys-
tems mostly rely on exploiting the enhanced permeability and
retention (EPR) effect, which exists due to the high leakiness
a)Author to whom correspondence should be addressed. Electronic mail:
khizroev@fiu.edu. Telephone: 1-305-348-3724.
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of tumor blood vessels and the lack of a lymphatic system for
drainage.11–14 The delivery specificity can be further improved
by adding an active delivery mechanism, for example, through
conjugating nanoparticles with monoclonal antibodies (mAbs)
tailored to recognize over-expressed tumor-specific bio-
markers.15–21 In addition, nanoparticles must be able not only
to provide high-specificity targeted delivery but also to ensure
that the therapeutic load is not prematurely released in the
plasma or interstitial space before it reaches the intended tar-
get.22–25 Therefore, nanoparticles have been further functional-
ized to control drug release by externally applied
temperature,26,27 ultrasound,28,29 intracellular pH level,30 intra-
cellular enzymes,31 or magnetic fields.32–35 Nevertheless, all
these approaches still have inadequately low efficacy.
In parallel, there has been a focus on using the phenome-
non of electroporation for enabling a high-efficacy high-spe-
cificity cellular uptake of a drug.36–43 In this case, an electric
field above a cell-specific threshold causes a dielectric break-
down of the cell membrane.44 This breakdown field is differ-
ent for cancer and normal cells of the same type. For example,
application of an electric field on the order of 1 kV/cm can
create sufficiently large pores allowing for an enhanced cellu-
lar uptake of molecules by cancer cells while it takes a factor
of two or five higher field to achieve this effect in the normal
cells. Although very promising, the electroporation involves
relatively high electric fields at a relatively large scale and
thus comes with a collateral damage.
Based on an analysis of recent studies,45–49 combined
with a new study on using liquid-environment atomic force
microscopy (AFM) to study the interaction between nanopar-
ticles and the cellular membranes, this paper presents a basic
physics model to help understand how a class of multiferroic
nanoparticles known as magnetoelectric nanoparticles
(MENs) could address the above challenges.50–53 Indeed,
MENs provide (a) a targeting mechanism driven by a physi-
cal force rather than antibody matching, (b) a delivery mech-
anism that enhances cellular uptake of a therapeutic load
across the cancer cell membranes only, without affecting
normal cells, (c) an externally controlled mechanism that
releases the load on demand, last but not least (d) due to the
presence of a magnetic moment, they can be used for image-
guided therapy. With the above said, MENs present a novel
platform to treat cancer not from the perspective of bioinfor-
matics but rather from the perspective of the molecular-level
physics of the interaction between nanoparticles and cellular
microenvironment. Such an approach, hereinafter referred to
as technobiology, is complementary to the traditional bio-
technology approach.
II. UNDERLYING PHYSICS
A. Difference between MENs and magnetic
nanoparticles (MNPs)
MENs must not be confused with traditional magnetic
nanoparticles (MNPs), e.g., superparamagnetic iron oxide
nanoparticles (SPIONs)54–57 or other superparamagnetic and
non-superparamagnetic ferromagnetic or ferrimagnetic nano-
structures used for targeted delivery or magnetic imag-
ing.58–61 Like MNPs, MENs have a non-zero magnetic
moment and therefore can be transported via application of
an external d.c. magnetic field with a non-zero spatial gradi-
ent. Also, the negative feedback loop required for image-
guided navigation can be closed through existing magnetic
imaging techniques such as magnetic resonance imaging
(MRI) or magnetic particle imaging (MPI).62–64 However,
unlike MNPs, MENs offer a novel functionality—an energy-
efficient control of intrinsic electric fields in close proximity
to the nanoparticles via application of external d.c. and a.c.
magnetic fields. Due to the magnetoelectric effect (ME)
effect, MENs allow an external control of the electric fields
that underlie the intrinsic molecular interactions between
specific cells and the drug-loaded nanoparticles as well as
the interaction between MENs and the loaded drug. An
immediate consequence of this capability is the freedom to
engineer an adequately strong bond between the nanopar-
ticles and the drug to avoid an undesired release of the thera-
peutic load before it reaches the target; only when an a.c.
magnetic field is applied, this strong bond is “turned off” on
demand. This mechanism of using an a.c. field to controlla-
bly break the bond between MENs and the load has been pre-
viously described with regard to the topic of delivery of
antiretroviral therapy across the blood-brain barrier (BBB) to
treat HIV-1 virus hidden deep in the brain.65 In addition, due
to the ME effect, using MENs opens a pathway to exploit
intrinsic electric properties of the cell membrane at the nano-
scale for enabling targeted high-specificity delivery without
relying on any bioactive mechanism. The cell membrane,
consisting of numerous ion channels, is an electrically polar-
izable medium, and its electric charge strongly depends on
the cellular microenvironment, e.g., its pH level. As a result,
cellular properties can be significantly and differently (for
normal and cancer cells) affected by local electric fields.66,67
This difference is the basis for using electroporation for
inducing a high-specificity drug uptake by cancer cells.
According to the conventional approach to an
electroporation-based cancer treatment, a relatively large
electric field, on the order of 1000V/cm, is applied at the
macroscale, which inevitably results in undesired side
effects. With MENs, this property of electroporation can be
scaled down to the nanoscale. As a result, the MEN-induced
electroporation, hereinafter referred to as nanoelectropora-
tion, would result in significantly reduced side effects
because the relatively high field is limited to the nanoscale
region in proximity to each nanoparticle. In addition, the spe-
cificity factor (SF), defined as the ratio of the average num-
ber of nanoparticles penetrated into a cancer cell versus the
average number of nanoparticles penetrated into an adjacent
normal cell under equivalent conditions, can be significantly
increased in the case of the nanoelectroporation, as discussed
below in more detail. Due to this nanoelectroporation ability,
MENs not only further improve the specificity of the EPR-
based delivery but also add another targeting mechanism to
enable passive delivery at the intracellular level and thus
pave a way to treatment of both primary and secondary
tumors at different cancer progression levels. Last but not
least, because of the fundamental nature of this externally
controlled approach, MENs can be used to treat all kinds of
cancers including fast-progressing brain tumors and other
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solid and liquid tumors. Brachytherapy would be one example
of a current approach which could be completely replaced by
MENs. Brachytherapy uses a sealed radioactive pellet, e.g.,
made of iridium, placed close to a tumor site through cathe-
ters.72 When activated, the pellet emits radiation which kills
both cancer and normal cells a few millimetres away. Using
field-activated MENs instead of the strongly radioactive pellet
can significantly improve the specificity of the treatment and
thus reduce or eliminate side effects.
B. Synthesis and characterization of MENs
MENs can be synthesized according to standard chemi-
cal procedures described in previous studies. One of the
most popular room-temperature configurations is the core-
shell nanostructure made of a magnetostrictive core, e.g.,
CoFe2O4, and a piezoelectric shell, e.g., BaTiO3.
68–71 By
default, in this paper, the average size of MENs is approxi-
mately 30 nm and the average size of the core is approxi-
mately 10 nm. X-Ray diffraction (XRD) measurements have
confirmed the cubic and tetragonal crystal structures of the
core and shell, respectively. Depending on a specific applica-
tion, whether it is for a drug delivery, a neural stimulation, or
3D navigation and/or imaging, MENs can be further coated
with thin functionalization layers serving as linkers to the
therapeutic load or to enable hydrophilic or hydrophobic sur-
face suitable for the microenvironment of interest. The ME
coefficient, a, for these nanostructures is known to be in a
range from 10 to over 100mV cm1Oe1, depending on the
phase compositions and the quality of the interface between
the core and the shell. The saturation magnetization of these
particular MENs is on the order of 10 emu/g, which is an
order of magnitude smaller than that for high-moment iron
oxide nanoparticles. Considering the core is made of a rela-
tively high anisotropy structure, these MENs are not super-
paramagnetic and have a room temperature coercivity on the
order of 100Oe. On a final note, it is worth noting that in
general MENs are not limited to this particular composition.
There are many other compositions which display a non-zero
ME effect. Furthermore, it is likely that in the future MENs
will be made of biodegradable organic materials; for exam-
ple, carbon based nanostructures have already been shown to
display a non-zero ME effect.73
C. Targeting by MENs
In general, there are two fundamentally different
approaches to targeting with MENs, using local and systemic
administration of nanoparticles, respectively. For the local
administration, MENs could be either directly injected into a
tumor site or navigated to the target site via application of
localized magnetic fields after the nanoparticles are adminis-
trated in the vasculature. For example, it has been shown that
using MRI-guided navigation with a pulsed sequence of field
gradients, magnetic nanoparticles could be localized at any
point in a 3D space with a spatial precision of less than
0.1mm.74 For the systemic administration, MENs could be
administrated intravenously. In either case, the delivery and
uptake specificity could be further significantly improved
due to the following physics.
Unlike purely active delivery approaches, e.g., using
mAbs, T-cells (CAR T-Cell), or cancer vaccines, MENs
offer a passive delivery mechanism, which is complementary
to the well-known EPR effect.75 The EPR effect ensures
delivery of drug-loaded nanoparticles into relatively large
tumor aggregates but not in relatively small aggregates made
of one or few cancer cells. In contrast, due to a different
underlying physics, MENs-driven targeting works equally
well with cell aggregates and individual cells. Because
MENs generate their own electric fields, which in turn can
be controlled by external magnetic fields, they can specifi-
cally electroporate cancer cells without affecting surround-
ing normal cells, as described below in more detail. In this
case, the localization range of the nanoparticle-generated
electric field is defined by the nanoparticle’s average size,
which is approximately 30 nm. In turn, this localization
range is orders of magnitude smaller than the characteristic
cell size, which is on the order of a few microns. Therefore,
MENs could be used to target primary and metastasized can-
cer cells even at a very early stage of cancer progression.
Last but not least, because of the existence of an externally
controlled surface charge, MENs bring another dimension to
targeted delivery; not only can they increase the specificity
factor but also can provide new functions of externally con-
trolled cancer cell penetration and drug release via applica-
tion of external magnetic fields. In a trivial approximation,
the electric field generated by a MEN at a point on the cell
membrane consists of two terms:
E ¼ k 3 p  r^ð Þ^r  p
r3
þ kQ
r2
r^; (1)
where k is the Coulomb constant, Q and p are the MEN’s
electric charge and dipole moment, respectively, and r is the
distance between the nanoparticle and the observation point
on the membrane. The first term is determined by the
magnetic-field dependent electric dipole moment due to the
ME effect, p¼ aH, where a is the ME coefficient and H is
the external magnetic field. The second term is determined
by the surface electric charge which is formed according to
the colloidal chemistry when MENs are placed in a solution,
e.g., the blood or the lymph. In this case, a double charged
layer is formed around the nanoparticle’s surface because of
the interplay of chemical and electrical forces. The surface
charge can be determined by measuring Zeta potential.
Furthermore, previously it has been shown that this surface
charge can be further increased with an external magnetic
field increase; in other words, the field dependence of the
surface charge also depends on the ME effect. It can be noted
that the surface charge term has a more significant effect
because it drops with a distance substantially slower (1/r2)
compared to the dipole charge term (1/r3).
Because both MENs and the cell membranes have the
same charge polarity, MENs can easily go through a capil-
lary without being engulfed by the surrounding cells.
However, when MENs are in close proximity to the cell
membranes (within a distance on the order of a micron), their
electric field (on the order of 0.1V/lm, as shown below
mostly due to the charge) is sufficiently strong to induce a
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local dielectric breakdown in the cancer cells but not too
strong (1.5V/lm) where it may cause this effect in the nor-
mal cells. This dielectric breakdown is reflected in a local
change of the lipid bilayer of the cellular membrane. Such a
field-dependent local change leads to cellular uptake of the
drug-loaded nanoparticles through the membrane surface.
Indeed, it is known that the conductivity of the intermediate
cancer cell membrane is by three orders of magnitude larger
than that of the normal cell membrane.77 The high-
conductivity membrane induces a local attraction force
between MENs and the cancer cell due to the electrostatic
“mirror” effect. Here, it is worth noting that this nanoelectro-
poration effect could be further increased through application
of a pulsed magnetic field sequence. In this case, the interme-
diate high-conductivity breakdown state effectively lasts lon-
ger and thus the efficacy of this treatment is significantly
increased. That is the reason why the a.c. field application
might be more effective compared to the d.c. field application.
However, to simplify the explanation, the following descrip-
tion is focused on the d.c. case. In a first order approximation,
there are two distinct states of the membrane. In its normal
state, the membrane is non-conducting. In this case, the nega-
tively charged MENs are pushed away from the negatively
charged membrane surface. On the contrary, during the inter-
mediate nanoelectroporation process, the membrane surface
of the cancer cells is conducting and thus MENs are attracted
to the cancer cells. According to the “mirror image” model,
the attraction force could be estimated with this expression,
Fmirror ¼ kQ2=4r2; (2)
where the factor 1=4 is due to the fact that the effective distance
between the real and image charges is 2r, while r is the dis-
tance between the nanoparticle and the membrane surface.
Furthermore, as previously shown, the effective surface
charge and thus this attraction force can be further increased
with an increase in the externally applied magnetic field. This
magnetic field dependence of the charge can be found through
an experimental measurement of Zeta potential, V(H), in a
phosphate buffer solution (PBS) with a pH level similar to
that in the blood, Q¼V(H)d/k. Now, it is possible to estimate
the cut-off distance between the nanoparticle and the mem-
brane surface, rC, below which the electric field would be
above the nanoelectroporation threshold on the order of 0.1V/
lm for the cancer cells: rC¼ 0.5(kQ/E)1/2. For example, it has
been shown that application of a magnetic field on the order
of 300Oe could increase the cut-off distance by a factor of
two. Such an increase would significantly increase the number
of the nanoparticles capable of triggering local nanoelectropo-
ration and consequently would significantly increase the spe-
cificity factor of targeted delivery. This concept of MEN-
based targeting is illustrated in Figure 1. It could be noted that
this overly simplified theory does not take into account the
laminar flow in the circulation.
D. Drug release on demand
After the drug-loaded MENs enter the cancer cells, the
drug can be released off the nanoparticles on demand via
application of an a.c. external magnetic field. In this case, as
previously shown, even a relatively small magnitude a.c.
field (50Oe) in the near-d.c. frequency ranging from 10 to
over 100Hz is sufficiently strong to release substantial
amount of the drug into the cancer cells. It has been hypoth-
esised that application of an a.c. field “shakes” the drug off
the nanoparticles by significantly weakening the electric-
field bond which holds the two together, as illustrated in Fig.
2. According to the trivial model, the electric dipole moment
induced by an external magnetic field due to the ME effect is
DP¼ aH; therefore, the displaced surface charge density on
the diametrically opposite side of the nanoparticle would be
rME6aH. In other words, the magnetically triggered elec-
tric dipole moment breaks the symmetry of ionic bonds
around the nanoparticle. To a zeroth approximation, when
the displaced surface charge is comparable to the charge
involved in an original bond, rMEQionic/pd2, the bond can
be broken. Then, the threshold magnetic field amplitude to
break a bond can be evaluated according to this simple
expression:
Hth  Qionic=pd2a; (3)
FIG. 1. Illustration of the dependence
of the cutoff distance, rc, on applica-
tion of an external d.c. magnetic field,
H. (a) The nanoparticles within this
distance from the membrane surface
target the cancer cells due to the high-
specificity nanoelectroporation effect.
(b) The distance is increased with an
increase in the magnetic field.
FIG. 2. Illustration of the drug release mechanism via application of an a.c.
magnetic field.
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where d is the diameter of the nanoparticle, a is the ME coef-
ficient, and Qionic is the displaced charge in the ionic bond.
Application of an a.c. field would break the bonds in all the
orientations around the nanoparticle.
Here, it is worth reminding that it is imperative to
release the drug off MENs to increase the drug bioactivity
only after the drug-loaded MENs penetrate the cancer
cells.76 In other words, MENs enable a drug retention control
via application of external magnetic fields; the initial step of
high-specificity cellular penetration and the final step of drug
release off MENs are triggered via application of d.c. and
a.c. fields, respectively.
In summary, the above described three-step field-con-
trolled process for targeted drug delivery and release, respec-
tively, is illustrated in Fig. 3.
III. SUPPORTING EXPERIMENTS
A. Confocal microscopy study of high-specificity
cellular penetration
The purpose of the first described in vitro experiment was
to show how an external d.c. magnetic could be used to induce
a penetration of drug-loaded MENs into cancer cells. A popu-
lar mitotic inhibitor paclitaxel (PTX) was used as the therapeu-
tic load. In the described microscopy experiments, the PTX’s
fluorescent version known as Flutax-2 was imaged at 488 nm
(green color). A multidrug resistant cancer cell line MES-SA/
DX5 was used to test the field-induced penetration. For com-
parison, similar images were taken for two other cases with
cells incubated under equivalent conditions without any drug
and just with the drug, respectively. Microscopy images of the
two control cases and the cells incubated with MENs without
and with exposure to a d.c. field of 30Oe for approximately 12
h are shown in Figs. 4(a)–4(d), respectively. The optically
measured percentages of the drug uptake per mg of protein in
the four cases were 0, less than 0.3%, less than 0.2%, and
more than 6%, respectively. According to the procedures of
the experiment, the green light could be seen only from the
drug coming from inside the cells, because all the extracellular
material was washed away. The experiment clearly showed a
strong field dependence of the cellular uptake of the drug-
loaded MENs. Indeed, the uptake of the drug increased from
less than 0.2% to over 6%, i.e., by a factor of 30, after applica-
tion of a relatively small d.c. field of 30Oe.
Another experiment was conducted to demonstrate a high-
specificity cellular uptake with MEN-based delivery on ovar-
ian cancer and normal cell lines SKOV-3 and HOMEC,
respectively. The optically measured drug uptake depending
on the applied d.c. magnetic field for cancer and normal cells
is shown in Fig. 5. Indeed, it could be observed that there was
a significant field range, from 50Oe to 500Oe, when visi-
bly large amount of the drug penetrated the cancer cells while
barely any drug penetrated the normal cells. As mentioned ear-
lier, the effect of nanoelectroporation could be further
increased via application of a periodic sequence of magnetic
field pulses to effectively prolong the membrane’s intermediate
dielectric breakdown state which leads to the nanoparticles’
cellular uptake. Application of an a.c. magnetic field partially
mimics this pulsed sequence effect.53 Indeed, this a.c. field
dependence was demonstrated in the same experimental study.
Another experiment which demonstrated the field-
dependent cellular penetration of MENs was conducted with
FIG. 3. Illustration of a field-
controlled targeted drug (PTX) deliv-
ery and release by MENs.
FIG. 4. Confocal microscopy imaging of the uptake of Flutax-2 by cell line MES-SA/DX5 for four different drug-delivery-system combinations: (a) no drug,
(b) free Flutax-2 (drug uptake per mg of protein: <0.3%), (c) MENs loaded with Flutax-2 with no field (<0.2%), and (d) MENs loaded with Flutax-2 in a
30Oe d.c. field (>6%). The scale bar is approximately 50 um.
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atomic force microscopy (AFM) and magnetic force micros-
copy (MFM) imaging of cell lysates. This experiment
directly confirmed the presence of MENs inside cancer cells
only after application of a 100-Oe d.c. field.
B. Drug release off MENs via application of an a.c.
field
The purpose of the following experiments was to prove
that the therapeutic load could be released off MENs via
application of an a.c. magnetic field. Consequently, the func-
tion of the drug release could be physically separated from
the function of high-specificity targeting, in turn, achieved
via application of a d.c. field.
In one experiment, the amount of the released drug (pac-
litaxel) was measured spectrophotometrically at its maxi-
mum absorption wavelength of approximately 230 nm. It is
known that the bioactivity of the drug significantly increases
after the release due to the increased “free” surface area. The
dependence of the released drug on the strength and fre-
quency of the a.c. field ranging from 12 to 66Oe and 0 to
1000Hz, respectively, for different application times ranging
from 1 min to 2 h, is shown in a chart in Fig. 6.
Other experiments to confirm the drug release via
application of an a.c. field were based on Fourier-transform
infrared (FTIR) spectroscopy and X-ray diffraction (XRD)
measurements.
C. Liquid-environment atomic force microscopy study
of the nanoparticle-cell interaction
A liquid environment atomic force microscopy (AFM)
study was conducted with the goal to directly measure the
surface of cancer and normal cells under different experi-
mental conditions. In the following experiment, glioblastoma
(U87-MG) and endothelial cells were used as the cancer and
normal cells, respectively. Glioblastomas represent the most
frequent primary brain tumors while endothelial cells are
characteristic normal brain cells. It was already demonstrated
that drug-loaded MENs could be navigated across the blood-
brain barrier (BBB) via application of a sufficiently strong
d.c. magnetic field gradient (on the order of 1000Oe/cm)
with the subsequent controlled release of the drug after the
nanoparticles are placed deep in the brain.65 Typical AFM
images of endothelial and glioblastoma cells are shown in
Figs. 7(a) and 7(b), respectively. It can be noted that the nor-
mal cells have a more continuous surface morphology com-
pared to the cancer cells with clearly visible striations with a
characteristic size on the order of 100 nm.
Another AFM experiment was conducted to under-
stand how MENs penetrated the cancer cells. MENs were
added into media with glioblastoma cells through a special
Multimode liquid environment microprobe container.
Here, it is worth noting that usually when nanoparticles or
other nanoscale foreign reagents get attached to the mem-
brane surface, they quite rapidly (within seconds) move
across the membrane and penetrate the cell. The exact ori-
gin of this process still remains an open question; it might
FIG. 5. Optically measured (with a fluorometer) field dependence of the
drug uptake per mg of protein for cancer and normal cell lines SKOV-3 and
HOMEC, respectively.
FIG. 6. The dependence of the release of the drug, paclitaxel, on the a.c.
field strength and frequency for five different application times: 1, 5, 10, 60,
and 120 min. The data were measured spectrophotometrically as the absor-
bance at 230 nm wavelength.
FIG. 7. AFM image pair (z height and phase (right)) for (a) endothelial and
(b) glioblastoma cells.
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be defined either by a chain signalling between biomole-
cules within the cell or by some electric field effects in the
membrane and the cellular plasma or a combination of
these two effects. It is not trivial to use AFM to observe
the fast dynamic of the nanoparticle-cell interaction. To
slow down the cellular uptake of the nanoparticles, this
experiment was conducted at a relatively high concentra-
tion of MENs to ensure the cells are saturated and as a
result the nanoparticles become visible on the membrane
surface. An important observation of this experiment was
the fact that the nanoparticles preferred to penetrate the
cancer cell through the striations in the cellular membrane,
as shown in Fig. 8.
Last but not least, it could be mentioned that MENs
operate at relatively low fields and frequencies and thus do
not cause significant heating effects, as was confirmed
through infrared measurements of the cell surface at different
concentrations of MENs under different field exposures.
IV. CONCLUSION
The discussed experiments have demonstrated that
MENs could be used for externally controlled targeted drug
delivery and release. Furthermore, these two important func-
tions, i.e., delivery and release, could be physically separated
via application of d.c. and a.c. external magnetic fields,
respectively, as indicated by the hypothesised theory and
confirmed by a number of independent experiments. For
example, confocal microscopy studies have directly con-
firmed that the penetration of MENs into cancer cells occurs
only after the application of a d.c. magnetic field on the order
100Oe, while numerous spectrophotometry measurements
have shown that the drug is released off the nanoparticles
only after the application of an a.c. magnetic field with a
strength on the order of 50Oe and a near-d.c. frequency of
100Hz. As for the high-specificity delivery, one of the most
important characteristics of MENs is their ability to deliver
drugs specifically into the cancer cells without affecting the
surrounding normal cells. The penetration fields due to the
nanoelectroporation, i.e., the mechanism according to which
the delivery takes place, are different for the two cell forms,
i.e., cancer and normal cells, respectively, because their
membranes have different surface morphologies and charge
configurations, as shown through transport measurements
and AFM studies. As a result, it takes a significantly higher
field to break the dielectric barrier of the normal cell mem-
branes compared to that of the cancer cells. As mentioned
above, it is well known that even at the macroscale, the can-
cer cells have a smaller threshold field for the electroporation
compared to their normal counterparts; the difference is a
factor of two to five depending on the cancer type. The dis-
cussed experiments with MENs have shown that at the nano-
scale the difference becomes even more significant. For
example, for the ovarian and normal cancer cell lines,
SKOV-3 and HOMEC, respectively, it takes less than
100Oe and significantly more than 1000Oe, respectively, to
induce the nanoelectroporation via the ME effect. That is the
reason why we refer to the electroporation (by MENs) at the
nanoscale as the nanoelectroporation. The nanoelectropora-
tion seems to have a significantly higher specificity factor
compared to the traditional electroporation effect which
takes place at the macroscale. The AFM imaging of equiva-
lent glioblastoma cancer and normal endothelial cells has
shown very different surface topographies for the two cell
types; the normal cells are more continuous compared to the
cancer cells which in turn have visible striations of the char-
acteristic size on the order of 100 nm. The AFM images have
also shown that 30-nm MENs tend to accumulate in these
striations and thus penetrate the cell through these striations.
The fact that the nanoparticles penetrate the cancer cells
through the small striations in the membrane might explain
why the ratio between the nanoelectroporation threshold
fields between cancer and normal cells is more significant
(10) compared to that for the traditional electroporation at
the macroscale (2–5). It is worth noting that due to the
intrinsic nature of the ME coupling in the multiferroic nano-
structures, the magnetic field strength on the order of
100Oe, required for enabling the high-specificity delivery
and release functions, is substantially below any harmful
limits as per US Food and Drug Administration (FDA) regu-
lations.78 Eventually, because of the fundamental nature of
this approach, it can be applied to any cancer type. Last but
not least, it can be mentioned that most current studies have
been performed with MENs of the same coreshell composi-
tion, i.e., CoFe2O4–BaTiO3. These experiments have been
vital to demonstrate the feasibility of the MEN-based cancer
treatment approaches. In the future, other compositions can
be explored, e.g., ones made of biodegradable organic
materials.
V. MATERIALS AND PROCEDURES
A. Chemical synthesis of MENs
CoFe2O4-BaTiO3 core shell MENs were prepared
according to a polyvinylpyrrolidone assisted hydrothermal
method. First, 0.058 g of Cobalt Nitrate Hexahydrate
(Co(NO3)26H20) and 0.16 g of Ferric Nitrate Nonahydrate
(Fe(NO3)39H20) were dissolved by stirring in 15 ml of dis-
tilled water. Polyvinylpyrrolidone (PVP), 0.2 g, was dis-
solved in 5 ml of aqueous solution containing 0.9 g of
sodium borohydride. The PVP-sodium borohydride solution
was added dropwise to the above solution and the mixture
was stirred at 120 C until the liquid phase evaporated.
FIG. 8. AFM image pair (z height and phase (right)) for glioblastoma cells
with MENs found in striations on the surface membrane. The observed
nanoparticles are approximately 30-nm in diameter.
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CoFe2O4 particles were recovered, dispersed in distilled
water through sonication, and washed 3 times using mag-
netic separation. Purified CoFe2O4 cores were dried at
120 C for 24 h and stored at room temperature until further
use. The Barium Titanate (BaTiO3) shell was prepared using
the citrate gel method. Briefly, CoFe2O4 cores were dis-
persed in distilled water through sonication. Barium
Carbonate (BaCO3), 174mg, was dissolved in 60ml deion-
ized water containing 1 g of citric acid. This solution was
mixed with a 150ml ethanolic solution of titanium (IV) iso-
propoxide (284ll) and 6 g citric acid. The BaTi precursor
solution was added to the cores and sonicated at room tem-
perature for 1 h. The translucent yellow liquid was stirred at
70 C until the liquid phase evaporated completely. Finally,
the gel was calcined at various temperatures ranging from
500 to 800 C (CMF-1100) for 5 h and cooled naturally to
room temperature. The gelation temperature and the final
temperature were important determinants of the crystal struc-
ture and the final size of CoFe2O4-BaTiO3 core shell MENs.
For example, a temperature of 600 C was required for 30-
nm MENs.
B. Vibrating sample magnetometry
A cryogen-free 9-T vibrating sample magnetometer
(VSM) physical property management system from
Quantum Design was used to measure M-H loops and M-T
dependence in a temperature ranging from 1.9 to 400K.
C. Transmission electron microscopy (TEM)
A Phillips CM-200 200 kV Transmission Electron
Microscope (TEM) with an Energy Dispersive Spectroscopy
(EDS) option was used to obtain TEM images and EDS
profiles.
D. Atomic force microscopy
The imaging of both glioblastoma and brain endothelia
cells in a cellular microenvironment was conducted using a
MultiMode AFM system. Using a Bruker electrochemistry
fluid cell probe holder that has an integrated piezo element
for contact mode experiments and Bruker’s DNP-S10 sili-
con nitride probe, we were able to achieve the desired
results showing the interaction between MENs and the sur-
face of a cell. The DNP-S10 probe comes with four differ-
ent cantilevers of various dimensions each having a
different nominal spring constant value and resonant fre-
quency. The special C triangular shape cantilever was used
for cell imaging; the cantilever has a nominal resonant fre-
quency of 56 kHz and a nominal spring constant of 0.24N/
m which are ideal values for imaging stiff and firmly
attached samples. After placing the probe in the liquid solu-
tion, which for this experiment was phosphate buffer solu-
tion (PBS), the resonant frequency dropped to 8 kHz, i.e.,
an order of magnitude lower compared to the frequency in
air. After obtaining a lower resonant frequency, the probe
was engaged with the membrane surface for scanning at a
frequency rate of 0.100Hz and a scan size of 100 nm; these
two parameters were gradually increased until an adequate
quality image was obtained.
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